Epirubicin
About
Therapy type: Chemotherapy
Therapy strategy: Topoisomerase inhibition
Mappings
NCI Thesaurus: Epirubicin (coding:ncit:C62028)
RxNorm: epirubicin (coding:rxcui:3995, coding:omop:1344354)
SNOMED: Epirubicin (coding:sctid:417916005, coding:omop:4166710)
Therapeutic response
Precision oncology relationships for therapeutic response involving this therapy.
| Organizations | Biomarkers | Cancer types | Therapies | |
|---|---|---|---|---|
| FDA (4) HC (2) | HER2-positive | Invasive Breast Carcinoma | Cyclophosphamide, Docetaxel, Epirubicin, Fluorouracil, Pertuzumab, Trastuzumab | |
| FDA (2) HC (2) | HER2-positive | Invasive Breast Carcinoma | Cyclophosphamide, Epirubicin, Fluorouracil, Paclitaxel, Pertuzumab, Trastuzumab | |
| FDA (2) HC (2) | HER2-positive | Invasive Breast Carcinoma | Cyclophosphamide, Docetaxel, Epirubicin, Pertuzumab, Trastuzumab | |
| FDA (2) HC (2) | HER2-positive | Invasive Breast Carcinoma | Cyclophosphamide, Epirubicin, Paclitaxel, Pertuzumab, Trastuzumab |